Indication |
For the short-term treatment (up to 8 weeks) of active duodenal
ulcer, as well as maintenance therapy for duodenal ulcer patients at
reduced dosage (1 gram twice a day) after healing of acute ulcers. Also
used for the short-term treatment of gastric ulcer. |
Pharmacodynamics |
Sucralfate is a prescription medication used to treat peptic
ulcers. The current clinical uses of sucralfate are limited. It is
effective for the healing of duodenal ulcers, but it is not frequently
used for this since more effective drugs (e.g. proton pump inhibitors)
have been developed. Although the mechanism of sucralfate's ability to
accelerate healing of duodenal ulcers remains to be fully defined, it is
known that it exerts its effect through a local, rather than systemic,
action. Chemically, sucralfate is a complex of the disaccharide sugar,
sucrose, combined with sulfate and aluminum. In acidic solutions (e.g.
gastric acid) it forms a thick paste that has a strong negative charge. |
Mechanism of action |
Although sucralfate's mechanism is not entirely understood, there
are several factors that most likely contribute to its action.
Sucralfate, with its strong negative charge, binds to exposed
positively-charged proteins at the base of ulcers. In this way, it coats
the ulcer and forms a physical barrier that protects the ulcer surface
from further injury by acid and pepsin. It directly inhibits pepsin (an
enzyme that breaks apart proteins) in the presence of stomach acid and
binds bile salts coming from the liver via the bile thus protecting the
stomach lining from injury caused by the bile acids. Sucralfate may
increase prostaglandin production. Prostaglandins are known to protect
the lining of the stomach and may also bind epithelial growth factor and
fibroblast growth factor, both of which enhance the growth and repair
mechanism of the stomach lining. |
Absorption |
Minimally absorbed from the gastrointestinal tract (up to 5% of the disaccharide component and less than 0.02% of aluminum). |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Not Available |
Route of elimination |
The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. |
Half life |
Not known. |
Clearance |
Not Available |
Toxicity |
Acute oral toxicity (LD50) in mice is >8000 mg/kg.
There is limited experience in humans with overdosage of sucralfate.
Sucralfate is only minimally absorbed from the gastrointestinal tract
and thus risks associated with acute overdosage should be minimal. In
rare reports describing sucralfate overdose, most patients remained
asymptomatic. |